Sodium Glucose Transporter-2 (SGLT2) Inhibition to Prevent Cardiotoxicity?

Dr RR Baliga's "Got Knowledge Doc" Podkast · MasterMedFacts.com

July 29, 202213m 36s

Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Original episode page

Show Notes

Sodium Glucose Transporter-2 (SGLT2) Inhibition to Prevent Chemotherapy Induced Cardiotoxicity?

Dr RR Baliga's 'Got Knowledge Doc' PodKasts for Physicians

References

Scafoglio C, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015

Scafoglio CR, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018

Martinez CA, Scafoglio C. Heterogeneity of Glucose Transport in Lung Cancer. Biomolecules. 2020

Paternostro G, Camici PG, Lammerstma AA, Baliga RR, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest. 1996;98(9):2094‐2099.

Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure [published online ahead of print, 2020 May 6]. JAMA Cardiol. 2020

Fang JC. Heart-Failure Therapy - New Drugs but Old Habits?. N Engl J Med. 2019

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995‐2008.

← All episodes of Dr RR Baliga's "Got Knowledge Doc" Podkast